Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury
Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhag...
Saved in:
| Published in | Alzheimer's research & therapy Vol. 13; no. 1; pp. 58 - 27 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
07.03.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available.
We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL).
We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at - 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum.
This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. |
|---|---|
| AbstractList | Background Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available. Methods We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer’s disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL). Results We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90–123% recovery, dilution linearity of plasma specimens up to 32-fold with 96–112% recovery, spike recovery of 67–100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at − 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum. Conclusions This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available. We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL). We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 [degrees]C, 24 h at room temperature (RT), or 30 days at - 20 [degrees]C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum. This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available. We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL). We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at - 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum. This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. Abstract Background Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available. Methods We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer’s disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL). Results We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90–123% recovery, dilution linearity of plasma specimens up to 32-fold with 96–112% recovery, spike recovery of 67–100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at − 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum. Conclusions This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. Background Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available. Methods We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL). Results We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 [degrees]C, 24 h at room temperature (RT), or 30 days at - 20 [degrees]C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum. Conclusions This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. Keywords: GFAP, Plasma biomarker, TBI, CHIMERA, Immunoassay Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available.BACKGROUNDGlial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI), a leading cause of death and disability worldwide. In humans, serum or plasma GFAP levels can predict brain abnormalities including hemorrhage on computed tomography (CT) scans and magnetic resonance imaging (MRI). However, assays to quantify plasma or serum GFAP in preclinical models are not yet available.We developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL).METHODSWe developed and validated a novel sensitive GFAP immunoassay assay for mouse plasma on the Meso Scale Discovery immunoassay platform and validated assay performance for robustness, precision, limits of quantification, dilutional linearity, parallelism, recovery, stability, selectivity, and pre-analytical factors. To provide proof-of-concept data for this assay as a translational research tool for TBI and Alzheimer's disease (AD), plasma GFAP was measured in mice exposed to TBI using the Closed Head Impact Model of Engineered Rotational Acceleration (CHIMERA) model and in APP/PS1 mice with normal or reduced levels of plasma high-density lipoprotein (HDL).We performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at - 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum.RESULTSWe performed a partial validation of our novel assay and found its performance by the parameters studied was similar to assays used to quantify human GFAP in clinical neurotrauma blood specimens and to assays used to measure murine GFAP in tissues. Specifically, we demonstrated an intra-assay CV of 5.0%, an inter-assay CV of 7.2%, a lower limit of detection (LLOD) of 9.0 pg/mL, a lower limit of quantification (LLOQ) of 24.8 pg/mL, an upper limit of quantification (ULOQ) of at least 16,533.9 pg/mL, dilution linearity of calibrators from 20 to 200,000 pg/mL with 90-123% recovery, dilution linearity of plasma specimens up to 32-fold with 96-112% recovery, spike recovery of 67-100%, and excellent analyte stability in specimens exposed to up to 7 freeze-thaw cycles, 168 h at 4 °C, 24 h at room temperature (RT), or 30 days at - 20 °C. We also observed elevated plasma GFAP in mice 6 h after TBI and in aged APP/PS1 mice with plasma HDL deficiency. This assay also detects GFAP in serum.This novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD.CONCLUSIONSThis novel assay is a valuable translational tool that may help to provide insights into the mechanistic pathophysiology of TBI and AD. |
| ArticleNumber | 58 |
| Audience | Academic |
| Author | Stukas, Sophie Rowe, Elyn M. Cripton, Peter A. Button, Emily B. Barron, Carlos Bashir, Asma Cheung, Honor Cheng, Wai Hang Robert, Jerome Wellington, Cheryl L. Gill, Jasmine Baron, David C. Cooper, Jennifer |
| Author_xml | – sequence: 1 givenname: Emily B. surname: Button fullname: Button, Emily B. – sequence: 2 givenname: Wai Hang surname: Cheng fullname: Cheng, Wai Hang – sequence: 3 givenname: Carlos surname: Barron fullname: Barron, Carlos – sequence: 4 givenname: Honor surname: Cheung fullname: Cheung, Honor – sequence: 5 givenname: Asma surname: Bashir fullname: Bashir, Asma – sequence: 6 givenname: Jennifer surname: Cooper fullname: Cooper, Jennifer – sequence: 7 givenname: Jasmine surname: Gill fullname: Gill, Jasmine – sequence: 8 givenname: Sophie surname: Stukas fullname: Stukas, Sophie – sequence: 9 givenname: David C. surname: Baron fullname: Baron, David C. – sequence: 10 givenname: Jerome surname: Robert fullname: Robert, Jerome – sequence: 11 givenname: Elyn M. surname: Rowe fullname: Rowe, Elyn M. – sequence: 12 givenname: Peter A. surname: Cripton fullname: Cripton, Peter A. – sequence: 13 givenname: Cheryl L. surname: Wellington fullname: Wellington, Cheryl L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33678186$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1u1DAQhSNURH_gBbhAlpBQkUhx4jiJbypVhZZKleACrq2JY2-9cuzFdir1SXhdZndL6VYI5SKjyXeOJ-NzWOz54HVRvK7oSVX17cdUsUrwktZVSWknWCmeFQdVx_tSVILtPar3i8OUlpS2bd03L4p9xtquR4uD4tcnfatdWE3aZxIMAeIDNj6QpH2y2d5qkiP45CDb4MERO02zD5AS3JEcyKizVpmsHKQJyMJZRIwdonUO4h0BZUeryCqGrK0nx5cXZ9_eEzBZRzLN0fqN_TyhuyJDBGSsX87x7mXx3IBL-tX9-6j4cfH5-_mX8vrr5dX52XWpuGhyaTStqRqVMZ0QXHWDqisFo2kNlgBj3RusRd8xavpWDYJ2fBCGD7zpDKiBHRVXW98xwFKuop1wbBnAyk0jxIWEiMM5LQ1rRtZUeuC8a7g20CrW18xUlOkWBEOv063Xah4mPSpcaQS3Y7r7xdsbuQi3Eu-u56JDg-N7gxh-zjplOdmkNK7S6zAnWTeiF4LytkH07RN0GeaIF4QUp7XgHRP8L7UA_AHrTcBz1dpUnrWc101N-Zo6-QeFz6gnqzBzxmJ_R_DukeBGg8s3Kbh5HZG0C755vJGHVfzJHwL1FlAxpBS1eUAqKtchl9uQSwy53IRcChT1T0TK5k0-cW7r_if9DbfqAt0 |
| CitedBy_id | crossref_primary_10_3390_bios12030172 crossref_primary_10_3390_molecules26113259 crossref_primary_10_1002_alz_14245 crossref_primary_10_1016_j_neuroimage_2024_120764 crossref_primary_10_3390_cells13161370 crossref_primary_10_1016_j_bbi_2024_09_030 crossref_primary_10_1016_j_surfin_2022_102400 crossref_primary_10_1089_neu_2023_0653 crossref_primary_10_1016_j_neuchi_2022_06_003 crossref_primary_10_1186_s12974_024_03128_1 crossref_primary_10_4049_jimmunol_2200893 |
| Cites_doi | 10.1001/jamaneurol.2016.0039 10.1186/s13024-020-00366-8 10.1186/s13195-020-00682-7 10.1001/jamanetworkopen.2020.13191 10.1089/neu.2016.4442 10.1016/S1474-4422(18)30415-0 10.1161/STROKEAHA.117.018409 10.1186/s13195-019-0497-9 10.1038/ncomms11934 10.1089/neu.2019.6831 10.1038/s41591-018-0297-y 10.1136/bmjpo-2019-000473 10.1016/j.jalz.2019.09.004 10.1038/s41380-020-0721-9 10.1002/alz.12061 10.1016/j.expneurol.2019.113116 10.1007/s00701-011-1175-2 10.1016/S0140-6736(20)30367-6 10.3233/JAD-180325 10.1016/S1474-4422(19)30282-0 10.1186/s13195-018-0461-0 10.1016/j.nbd.2006.08.017 10.1212/WNL.0000000000009985 10.1016/j.expneurol.2017.12.007 10.1038/nrneurol.2016.127 10.1038/nprot.2009.148 10.1016/S1474-4422(18)30231-X 10.1089/neu.2019.6375 10.1007/s11060-015-1978-8 10.1021/acs.jproteome.5b00213 10.1186/s13024-019-0337-1 10.1016/j.jalz.2018.07.222 10.3389/fneur.2015.00179 10.1089/neu.2020.7071 10.1089/neu.2013.3040 10.1371/journal.pone.0146540 10.1001/jamanetworkopen.2019.19771 10.1097/TA.0000000000002706 10.1227/NEU.0000000000001226 10.1186/s13054-015-1081-8 10.7554/eLife.29595 10.1038/s41598-018-33158-8 10.1016/S0022-2275(20)37227-8 10.1373/clinchem.2016.263335 10.1194/jlr.R037762 10.1186/s12916-014-0206-2 10.1212/WNL.0000000000006321 10.1038/s41582-018-0079-7 10.1016/j.expneurol.2020.113409 10.1186/s13024-017-0201-0 10.1212/WNL.0b013e318253d5c7 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13195-021-00793-9 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Proquest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals (WRLC) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1758-9193 |
| EndPage | 27 |
| ExternalDocumentID | oai_doaj_org_article_f34d341eb55745efa6c3823f103e6a93 PMC7938597 A655242055 33678186 10_1186_s13195_021_00793_9 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Canada United Kingdom--UK |
| GeographicLocations_xml | – name: Canada – name: United Kingdom--UK |
| GrantInformation_xml | – fundername: ; grantid: TR140070; TR192003 |
| GroupedDBID | --- 0R~ 23M 2WC 53G 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACJQM ACUHS ADBBV ADUKV AEAQA AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HZ~ IAO IEA IHR IHW INH INR ITC KQ8 M1P M~E O5R O5S O9- OK1 P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SBL SOJ TR2 TUS UKHRP -56 -5G -BR 3V. ACRMQ ADINQ C24 NPM PMFND 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c594t-fe020cdcff7995c7bc21cadf6f7bcaad28ff6f98730f86cb9075b9f5b547facb3 |
| IEDL.DBID | 7X7 |
| ISSN | 1758-9193 |
| IngestDate | Wed Aug 27 01:03:10 EDT 2025 Thu Aug 21 13:48:31 EDT 2025 Fri Jul 11 10:47:09 EDT 2025 Fri Jul 25 02:12:31 EDT 2025 Tue Jun 17 21:02:14 EDT 2025 Tue Jun 10 20:42:41 EDT 2025 Thu May 22 21:15:48 EDT 2025 Thu Jan 02 22:58:11 EST 2025 Thu Apr 24 23:09:43 EDT 2025 Tue Jul 01 02:38:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immunoassay TBI CHIMERA Plasma biomarker GFAP |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c594t-fe020cdcff7995c7bc21cadf6f7bcaad28ff6f98730f86cb9075b9f5b547facb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2502957395?pq-origsite=%requestingapplication% |
| PMID | 33678186 |
| PQID | 2502957395 |
| PQPubID | 2040174 |
| PageCount | 27 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_f34d341eb55745efa6c3823f103e6a93 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7938597 proquest_miscellaneous_2498990564 proquest_journals_2502957395 gale_infotracmisc_A655242055 gale_infotracacademiconefile_A655242055 gale_healthsolutions_A655242055 pubmed_primary_33678186 crossref_primary_10_1186_s13195_021_00793_9 crossref_citationtrail_10_1186_s13195_021_00793_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-07 |
| PublicationDateYYYYMMDD | 2021-03-07 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Alzheimer's research & therapy |
| PublicationTitleAlternate | Alzheimers Res Ther |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Lei (793_CR11) 2015; 19 H Hampel (793_CR1) 2018; 14 793_CR39 L Papa (793_CR24) 2016; 73 JP Posti (793_CR41) 2016; 79 FM Elahi (793_CR42) 2020; 16 DR Namjoshi (793_CR56) 2016; 11 A Abdelhak (793_CR14) 2018; 8 S Luger (793_CR18) 2017; 63 A Bashir (793_CR22) 2020; 324 M Riwanto (793_CR36) 2013; 54 JP Posti (793_CR47) 2017; 34 MD Sweeney (793_CR32) 2019; 15 Y Iturria-Medina (793_CR34) 2016; 7 793_CR43 793_CR46 793_CR45 SL James (793_CR53) 2019; 18 TPV Huynh (793_CR27) 2019; 14 WH Cheng (793_CR54) 2018; 301 793_CR48 JJ Bazarian (793_CR4) 2018; 17 J Tichy (793_CR15) 2015; 126 G Livingston (793_CR52) 2020; 396 M Garcia-Alloza (793_CR49) 2006; 24 JK Yue (793_CR8) 2019; 18 E Thelin (793_CR13) 2019; 36 P Oeckl (793_CR19) 2019; 67 J Attems (793_CR33) 2014; 12 P Shahim (793_CR31) 2020; 95 EH McNamara (793_CR21) 2020; 333 AH Katsanos (793_CR16) 2017; 48 793_CR55 MD Sweeney (793_CR28) 2020; 16 BM Asken (793_CR44) 2020; 37 MA Flierl (793_CR29) 2009; 4 J Robert (793_CR37) 2017; 12 793_CR3 SSM Gordon (793_CR51) 2015; 14 J Gill (793_CR7) 2018; 91 D Nation (793_CR35) 2019; 25 C Ren (793_CR17) 2016; 14 LM Lewis (793_CR9) 2020; 37 L Papa (793_CR25) 2019; 3 AS Plump (793_CR50) 1997; 38 793_CR23 M McCrea (793_CR26) 2020; 3 H Zetterberg (793_CR2) 2016; 12 J Žurek (793_CR10) 2012; 154 J Robert (793_CR38) 2020; 15 EB Button (793_CR30) 2019; 11 TN Anderson (793_CR5) 2020; 89 Z Metting (793_CR6) 2012; 78 IMW Verberk (793_CR20) 2020; 12 CL Pattinson (793_CR12) 2020; 3 R Diaz-Arrastia (793_CR40) 2014; 31 |
| References_xml | – volume: 73 start-page: 551 issue: 5 year: 2016 ident: 793_CR24 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.0039 – volume: 15 start-page: 23 issue: 1 year: 2020 ident: 793_CR38 publication-title: Mol Neurodegener doi: 10.1186/s13024-020-00366-8 – volume: 12 start-page: 118 issue: 1 year: 2020 ident: 793_CR20 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-020-00682-7 – volume: 3 issue: 8 year: 2020 ident: 793_CR12 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.13191 – volume: 34 start-page: 1427 issue: 7 year: 2017 ident: 793_CR47 publication-title: J Neurotrauma doi: 10.1089/neu.2016.4442 – volume: 18 start-page: 56 issue: 1 year: 2019 ident: 793_CR53 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(18)30415-0 – volume: 48 start-page: 2586 issue: 9 year: 2017 ident: 793_CR16 publication-title: Stroke. doi: 10.1161/STROKEAHA.117.018409 – volume: 14 start-page: 1 issue: 6 year: 2016 ident: 793_CR17 publication-title: Sci Rep – ident: 793_CR43 – volume: 11 start-page: 44 issue: 1 year: 2019 ident: 793_CR30 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-019-0497-9 – volume: 7 start-page: 11934 year: 2016 ident: 793_CR34 publication-title: Nat Commun doi: 10.1038/ncomms11934 – volume: 37 start-page: 1537 issue: 13 year: 2020 ident: 793_CR44 publication-title: J Neurotrauma doi: 10.1089/neu.2019.6831 – volume: 25 start-page: 270 issue: 2 year: 2019 ident: 793_CR35 publication-title: Nat Med doi: 10.1038/s41591-018-0297-y – ident: 793_CR3 – volume: 3 start-page: 1 issue: 1 year: 2019 ident: 793_CR25 publication-title: BMJ Paediatr Open doi: 10.1136/bmjpo-2019-000473 – volume: 16 start-page: 681 issue: 4 year: 2020 ident: 793_CR42 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2019.09.004 – ident: 793_CR48 doi: 10.1038/s41380-020-0721-9 – volume: 16 start-page: 821 issue: 6 year: 2020 ident: 793_CR28 publication-title: Alzheimers Dement doi: 10.1002/alz.12061 – volume: 324 start-page: 113116 year: 2020 ident: 793_CR22 publication-title: Exp Neurol doi: 10.1016/j.expneurol.2019.113116 – ident: 793_CR46 – volume: 154 start-page: 93 issue: 1 year: 2012 ident: 793_CR10 publication-title: Acta Neurochir doi: 10.1007/s00701-011-1175-2 – volume: 396 start-page: 413 issue: 10248 year: 2020 ident: 793_CR52 publication-title: Lancet. doi: 10.1016/S0140-6736(20)30367-6 – volume: 67 start-page: 481 issue: 2 year: 2019 ident: 793_CR19 publication-title: J Alzheimers Dis doi: 10.3233/JAD-180325 – volume: 18 start-page: 953 issue: 10 year: 2019 ident: 793_CR8 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(19)30282-0 – ident: 793_CR55 doi: 10.1186/s13195-018-0461-0 – volume: 24 start-page: 516 issue: 3 year: 2006 ident: 793_CR49 publication-title: Neurobiol Dis doi: 10.1016/j.nbd.2006.08.017 – volume: 95 start-page: e623 issue: 6 year: 2020 ident: 793_CR31 publication-title: Neurology. doi: 10.1212/WNL.0000000000009985 – volume: 301 start-page: 26 issue: Pt A year: 2018 ident: 793_CR54 publication-title: Exp Neurol. doi: 10.1016/j.expneurol.2017.12.007 – volume: 12 start-page: 563 issue: 10 year: 2016 ident: 793_CR2 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2016.127 – volume: 4 start-page: 1328 issue: 9 year: 2009 ident: 793_CR29 publication-title: Nat Protoc doi: 10.1038/nprot.2009.148 – volume: 17 start-page: 782 issue: 9 year: 2018 ident: 793_CR4 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(18)30231-X – volume: 36 start-page: 2850 issue: 20 year: 2019 ident: 793_CR13 publication-title: J Neurotrauma doi: 10.1089/neu.2019.6375 – volume: 126 start-page: 361 issue: 2 year: 2015 ident: 793_CR15 publication-title: J Neuro-Oncol doi: 10.1007/s11060-015-1978-8 – ident: 793_CR45 – volume: 14 start-page: 2686 issue: 6 year: 2015 ident: 793_CR51 publication-title: J Proteome Res doi: 10.1021/acs.jproteome.5b00213 – volume: 14 start-page: 37 issue: 1 year: 2019 ident: 793_CR27 publication-title: Mol Neurodegener doi: 10.1186/s13024-019-0337-1 – volume: 15 start-page: 158 issue: 1 year: 2019 ident: 793_CR32 publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2018.07.222 – ident: 793_CR23 doi: 10.3389/fneur.2015.00179 – volume: 37 start-page: 2624 issue: 24 year: 2020 ident: 793_CR9 publication-title: J Neurotrauma doi: 10.1089/neu.2020.7071 – volume: 31 start-page: 19 issue: 1 year: 2014 ident: 793_CR40 publication-title: J Neurotrauma doi: 10.1089/neu.2013.3040 – volume: 11 issue: 1 year: 2016 ident: 793_CR56 publication-title: PLoS One doi: 10.1371/journal.pone.0146540 – volume: 3 issue: 1 year: 2020 ident: 793_CR26 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2019.19771 – volume: 89 start-page: 80 issue: 1 year: 2020 ident: 793_CR5 publication-title: J Trauma Acute Care Surg doi: 10.1097/TA.0000000000002706 – volume: 79 start-page: 456 issue: 3 year: 2016 ident: 793_CR41 publication-title: Neurosurgery. doi: 10.1227/NEU.0000000000001226 – volume: 19 start-page: 362 issue: 1 year: 2015 ident: 793_CR11 publication-title: Crit Care doi: 10.1186/s13054-015-1081-8 – ident: 793_CR39 doi: 10.7554/eLife.29595 – volume: 8 start-page: 1 issue: 1 year: 2018 ident: 793_CR14 publication-title: Sci Rep doi: 10.1038/s41598-018-33158-8 – volume: 38 start-page: 1033 issue: 5 year: 1997 ident: 793_CR50 publication-title: J Lipid Res doi: 10.1016/S0022-2275(20)37227-8 – volume: 63 start-page: 377 issue: 1 year: 2017 ident: 793_CR18 publication-title: Clin Chem doi: 10.1373/clinchem.2016.263335 – volume: 54 start-page: 3227 issue: 12 year: 2013 ident: 793_CR36 publication-title: J Lipid Res doi: 10.1194/jlr.R037762 – volume: 12 start-page: 206 issue: 1 year: 2014 ident: 793_CR33 publication-title: BMC Med doi: 10.1186/s12916-014-0206-2 – volume: 91 start-page: E1385 issue: 15 year: 2018 ident: 793_CR7 publication-title: Neurology. doi: 10.1212/WNL.0000000000006321 – volume: 14 start-page: 639 issue: 11 year: 2018 ident: 793_CR1 publication-title: Nat Rev Neurol doi: 10.1038/s41582-018-0079-7 – volume: 333 start-page: 113409 year: 2020 ident: 793_CR21 publication-title: Exp Neurol doi: 10.1016/j.expneurol.2020.113409 – volume: 12 start-page: 60 issue: 1 year: 2017 ident: 793_CR37 publication-title: Mol Neurodegener doi: 10.1186/s13024-017-0201-0 – volume: 78 start-page: 1428 issue: 18 year: 2012 ident: 793_CR6 publication-title: Neurology. doi: 10.1212/WNL.0b013e318253d5c7 |
| SSID | ssj0066284 |
| Score | 2.3108752 |
| Snippet | Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain injury (TBI),... Background Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic brain... Abstract Background Glial fibrillary acidic protein (GFAP) has emerged as a promising fluid biomarker for several neurological indications including traumatic... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 58 |
| SubjectTerms | Alzheimer's disease Animal cognition Antibodies Biomarkers Brain Brain research CHIMERA Cytoskeletal proteins Dementia FDA approval Gene expression GFAP Health aspects Immunoassay Injuries Older people Plasma Plasma biomarker Proteins TBI Traumatic brain injury |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals (WRLC) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI7QnrggEK_CAkFCAgTVTpsmbY4DYlghgTiw0t6ivAxFs-1qp3PYX8LfxU47o6mQ4MKtatyqtR3HTuzPjL2wOtQ-Au1_lTGvgipzp73InQpBAlTggE50P39Rp2fVp3N5ftDqi3LCRnjgkXEnIKqAljY6KetKRrDK09EVFAsRldUJ5xPXvF0wNdpgpdDq7kpkGnWyKUSRKpExdCZEuFzPlqGE1v-nTT5YlOYJkwcr0Oo2uzW5jnw5fvIddiN2d9mvg6wf3gO3vOvxxlu-ocx0smV8oOVoPW368ZYKQnp0me01H3oeIp0i8Et0oi8s_75GdeRAZQCoHlfX3Po2tJ4nNIe2468-rpZfX_PUWJxf0EZ9ev024b5yR-0meNv9RDndY2erD9_en-ZTs4XcS10NOUR0HH3wAAQR52vny8LbAArw0tpQNoDXukGLAI3yDoNq6TRIJ6sarHfiPjvq-i4-ZHzRhND4BoSrIw4CkgggnLwYhEeXJWPFjvfGT0jk1BBjbVJE0igzysugvEySl9EZe7N_5nLE4fgr9TsS6Z6SMLTTDdQsM2mW-ZdmZewZKYQZC1L3lsAslZTo2CykzNjLREG2AH_A26mkAdlAqFozyuMZJc5hPx_eKZ2ZbMjGoHNaakkHqRl7vh-mJykvrov9FmkqjQEzOrHI1Aejju5_Wgh0RJA_Gatn2jvjynyka38khHFkIsqrfvQ_2PiY3SzTxBP5oj5mR8PVNj5BR25wT9Oc_Q3pM0kd priority: 102 providerName: Directory of Open Access Journals |
| Title | Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33678186 https://www.proquest.com/docview/2502957395 https://www.proquest.com/docview/2498990564 https://pubmed.ncbi.nlm.nih.gov/PMC7938597 https://doaj.org/article/f34d341eb55745efa6c3823f103e6a93 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdge-EFgfgKjGIkJEAQrYljJ3lCXbUyITFNiEl9s_y5BXVJadOH_SX8u9y5aWiEtLc0vlTJ3fl8Pt_9jpB3qrS5cR7jX6mLMyvSWJeGxVpYy73PvPZ4ovv9XJxdZt_mfN4F3NZdWuXOJgZDbRuDMfJjWKrTkuOx0pfl7xi7RuHpatdC4z45ROgyTOnK5_2GSwiwvbtCmUIcrxOWhHpk2EAjLlxcDhajgNn_v2XeW5qGaZN769DsEXnYOZB0spX4Y3LP1U_In73cH9p4qmjdwI3PdI356WjRaIuL0qIL_dEKy0IacJzVLW0bah2eJdAluNI3il4tQCmpx2IAUJLVLVWmspWhAdOhqumHr7PJxUca2ovTGwzXh7_fBPRXqrHpBK3qXyCtp-RydvpzehZ3LRdiw8usjb0D99FY4z0CxZlcmzQxynrh4VIpmxYerssC7IIvhNGwtea69FzzLPfKaPaMHNRN7V4QOi6sLUzhmc4dDHogYR7R8pxlBhyXiCQ73kvT4ZFjW4yFDPuSQsitvCTISwZ5yTIin_pnlls0jjupT1CkPSUiaYcbzepKdhNTepZZWMmd5jzPuPNKGDwa9cmYOaFKFpE3qBByW5ba2wM5EZyDezPmPCLvAwVaBPgAo7rCBmADYmsNKI8GlDCTzXB4p3SysyRr-U_vI_K2H8YnMTuuds0GaLISts3gygJTn291tP9oxsAdAf5EJB9o74Arw5G6ug4448BEkFf-8u7XekUepGFKsXicH5GDdrVxr8FRa_UozMYROTw5Pb_4Ab-mYjoKQY-_YTtEYA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFXSB3hBIC5DoYsEAgRWE693bT8glEJDSg9VqJX6tnivYpTaIYdQvoS_4BuZ2dghFlLf-mZ5x5Y9MzvHzkXIizwzibYOz78iG8ZGRKHKNAuVMIY7FzvlMKJ7dCyGZ_GXc36-Qf40tTCYVtnIRC-oTaXxjHwHVHWUcQwrfRj_DHFqFEZXmxEaS7Y4sItf4LJN3-9_Avq-jKLB3unHYVhPFQg1z-JZ6CxYSNpo57AXmk6Ujno6N044uMxzE6UOrsEVZ12XCq3Ae-Qqc1zxOHG5Vgzee4NsxgxcmQ7Z3N07PvnayH4hQNo3pTmp2Jn2WM9XQIPLjp3owqyl_vyUgP91wZoybCdqrmm-wR1yuzZZaX_JY3fJhi3vkd9r2Ua0cjSnZQU33tEpZsSjDKUzVIOj-rCRFliIUoGpni_orKLGYvSCjsF4v8zpxQi2AXVYfgBsOVnQXBem0NR3kShK-vrzoH_yhvqB5vQSAwT-9XPfb5YqHHNBi_IH8Md9cnYt5HhAOmVV2keEdlNjUp06phILiw5AmMP-fNYwDaZSQHoN7qWuO6DjII6R9J5QKuSSXhLoJT29ZBaQt6tnxsv-H1dC7yJJV5DYu9vfqCYXshYF0rHYgO1gFedJzK3LhcZgrOt1mRV5xgKyjQwhl4WwKwkk-4JzMKi6nAfklYdAGQQ_oPO6lALQgN28WpBbLUiQHbq93DCdrGXXVP7baQF5vlrGJzEfr7TVHGDiDBx1MJ4BqQ-XPLr6acbAAAL8BCRpcW8LK-2VsvjuO5sDEoFeyeOrP2ub3ByeHh3Kw_3jgyfkVuS3Fwu7yRbpzCZz-xTMxJl6Vu9NSr5dtzj4CzJfgpc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+novel%2C+sensitive+translational+immunoassay+to+detect+plasma+glial+fibrillary+acidic+protein+after+murine+traumatic+brain+injury&rft.jtitle=Alzheimer%27s+research+%26+therapy&rft.au=Button%2C+Emily+B&rft.au=Cheng%2C+Wai+Hang&rft.au=Barron%2C+Carlos&rft.au=Cheung%2C+Honor&rft.date=2021-03-07&rft.pub=BioMed+Central+Ltd&rft.issn=1758-9193&rft.eissn=1758-9193&rft.volume=13&rft.issue=1&rft_id=info:doi/10.1186%2Fs13195-021-00793-9&rft.externalDocID=A655242055 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-9193&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-9193&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-9193&client=summon |